El interés en corto de AvidXchange Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de AvidXchange Holdings. Los datos de interés en corto se actualizan cada dos semanas.

AvidXchange Holdings (NASDAQ:AVDX) Bolsa, Informe de interés en corto

AvidXchange Holdings

AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.

AvidXchange Holdings, Inc. - Common Stock

AvidXchange Holdings Inc

TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.15) by 460 percent. This is a 50.88 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $380.76 million which beat the analyst consensus estimate of $367.90 million by 3.50 percent. This is a 2.12 percent increase over sales of $372.86 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

TPIC

TPI Composites Q3 2024 Sales $380.76M Beat $367.90M Estimate

One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) raises FY2024 sales outlook from $700.00 million-740.00 million to $844.00 million-864.00 million.

Guidance

STKS

One Group Hospitality Raises FY2024 Sales Guidance from $700.00M-740.00M to $844.00M-864.00M

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) raises FY2024 sales outlook from $140.00 million-145.00 million to $143.00 million-145.00 million.

ADPT

Adaptive Biotechnologies Raises FY2024 Sales Guidance from $140.00M-145.00M to $143.00M-145.00M

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 47.5 percent increase over losses of $(0.40) per share from the same period last year.

RGLS

Regulus Therapeutics Q3 EPS $(0.21) Misses $(0.17) Estimate

Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) reported its first-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/b41823677/affirm-reports-first-fiscal-quarter-2025-results">figures from the quarter.   </a>
The Details: Affirm reported quarterly losses of 31 cents per share, which beat the analyst consensus estimate for losses of 35 cents. Quarterly revenue came in at $698.47 million which beat the analyst consensus estimate of $664.01 million and is an increase over sales of $496.54 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;We continued driving accelerated growth while delivering consistent credit outcomes and managing the business to our target of 3-4% RLTC as a percentage of GMV, which stood at 3.8% this quarter. Year-over-year GMV growth re-accelerated, and growth in active consumers accelerated for the third consecutive quarter,&#8221; said Max Levchin, Affirm&#8217;s CEO.
&#8220;Transactions per active consumer grew 25% year over year to 5.1, and trailing 12-month GMV per active consumer grew 11% year over year to $1,500. We continue to expect to reach GAAP Operating Income profitability in FQ4'25,&#8221; Levchin added.
Outlook:&nbsp;Affirm sees second-quarter revenue of between $770 million and $810 million and fiscal year 2025 GMV of more than $34 billion. 
AFRM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affirm shares are down 0.71% after-hours at $48.45 at the time of publication Thursday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Movers

AFRM

Affirm Reports Better-Than-Expected Q1 Results: Details

WIIM

INOD

Innodata shares are trading higher after the company reported better-than-expected Q3 financial results.

Lions Gate Entertainment Corporation Class B Non-Voting Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.65) by 33.85 percent. The company reported quarterly sales of $948.600 million which missed the analyst consensus estimate of $956.789 million by 0.86 percent. This is a 6.63 percent decrease over sales of $1.016 billion the same period last year.

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Lions Gate Entertainment Corporation Class B Non-Voting Shares Q2 2025 Adj. EPS $(0.43) Beats $(0.65) Estimate, Sales $948.600M Miss $956.789M Estimate

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. The company reported quarterly sales of $2.17 million which beat the analyst consensus estimate of $648.50 thousand by 234.62 percent. This is a 134.85 percent increase over sales of $924.00 thousand the same period last year.

DNTH

Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate

89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.64) by 117.19 percent. This is a 208.89 percent decrease over losses of $(0.45) per share from the same period last year.

ETNB

89bio Q3 EPS $(1.39) Misses $(0.64) Estimate

Agilon Health shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 60 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $641.141 thousand which beat the analyst consensus estimate of $375.000 thousand by 70.97 percent. This is a 73.91 percent decrease over sales of $2.457 million the same period last year.

CODX

Co-Diagnostics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $641.141K Beat $375.000K Estimate

ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $171.33 million which beat the analyst consensus estimate of $160.42 million by 6.80 percent. This is a 43.96 percent increase over sales of $119.01 million the same period last year.

ACVA

ACV Auctions Q3 EPS $(0.10) Beats $(0.11) Estimate, Sales $171.33M Beat $160.42M Estimate

Retail Sales

PRCH

Porch Group Announced That It Lowered Its FY24 Sales Guidance From $450M-470M to $440M-455M

SGHT

Sight Sciences Sees FY24 Revenue $81M-$83M Vs $82.16M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) raises FY2024 sales outlook from $318.00 million-325.00 million to $322.00 million-326.00 million.

Eventbrite Raises FY2024 Sales Guidance from $318.00M-325.00M to $322.00M-326.00M  VS Est.322.03M

Stock Split

ANET

Arista Approved Four-For-One Forward Stock Split

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $231.358 million which beat the analyst consensus estimate of $223.537 million by 3.50 percent. This is a 5.44 percent increase over sales of $219.419 million the same period last year.

CARG

CarGurus Q3 2024 Adj. EPS $0.45 Beats $0.42 Estimate, Sales $231.358M Beat $223.537M Estimate

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively.

ADMA

ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively

BSLK

Bolt Projects Holdings Q3 EPS $0.32

Narrows FY24 revenue view to $437M-$439M from $436M-$439M, consensus $437.22M. Published first on TheFly – the ultimate source for real-time, marke...

AvidXchange sees FY24 adjusted EPS 24c-25c, consensus 25c

AvidXchange Non-GAAP EPS of $0.07 in-line, revenue of $112.8M beats by $1.98M

AvidXchange Holdings, Inc. (AVDX) Q3 2024 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Trump Media (DJT) jumps after Donald T...

Trump Media, broader market surge after Trump wins election: Morning Buzz

Avidxchange Holdings, Inc. ( ($AVDX) ) has released its Q3 earnings. Here is a breakdown of the information Avidxchange Holdings, Inc. presented to...

AvidXchange Reports Strong Q3 2024 Financial Performance

In a report released today, Ramsey El Assal from Barclays maintained a Buy rating on AvidXchange Holdings (AVDX – Research Report), with a price ta...

Barclays Sticks to Their Buy Rating for AvidXchange Holdings (AVDX)

KeyBanc analyst Alex Markgraff maintained a Buy rating on AvidXchange Holdings (AVDX – Research Report) today. The company's shares closed yesterda...

KeyBanc Sticks to Their Buy Rating for AvidXchange Holdings (AVDX)

Piper Sandler analyst Brent Bracelin raised the firm's price target on AvidXchange (AVDX) to $10 from $9 and keeps a Neutral rating on the shares. ...

AvidXchange price target raised to $10 from $9 at Piper Sandler

As previously reported, Compass Point analyst Dominick Gabriele upgraded AvidXchange (AVDX) to Buy from Neutral with a price target of $15, up from...

AvidXchange upgraded to Buy at Compass Point on 'Street high' FY26 view

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

AAPL

ALGM

AVDX

CBOE

CELH

CROX

CTKB

DLTR

EXAS

FIVE

HNDAF

HNHAF

HNHPF

HUBS

IRBT

NTDOF

NTDOY

PACS

PLNT

RVLV

SMCI

SNOW

SRPT

STLA

TEVA

TNGX

TRMB

VANI

ZYME

Press Releases

AvidXchange and Workamajig Announce Exclusive Strategic Partnership to Empower Media Companies to Manage Invoices Seamlessly

AVDX Investigation: Kessler Topaz Meltzer & Check, LLP Encourages AvidXchange Holdings, Inc. (NASDAQ: AVDX) Investors with Significant Losses to Contact the Firm

Comments

AvidXchange Holdings

Interés en corto

AvidXchange Holdings (NASDAQ:AVDX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL